Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: November 2, 2012
Last updated: October 25, 2016
Last verified: October 2016
The purpose of this study is to compare the clinical benefit, as measured by overall survival, of nivolumab with that of. dacarbazine in patients with previously untreated, unresectable, or metastatic melanoma

Condition Intervention Phase
Biological: BMS-936558 (Nivolumab)
Biological: Placebo matching BMS-936558 (Nivolumab)
Drug: Dacarbazine
Drug: Placebo matching Dacarbazine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: From date of randomization to date of death. For those without documentation of death, to the last date the participant was known to be alive, assessed to 17 months. ]
    OS is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.

  • Overall Survival (OS) Rate [ Time Frame: Randomization to 6 months and 12 months ]
    OS rate is calculated as the percentage of participants who have not died divided by the total number of participants in the arm, based on Kaplan-Meier estimates

Secondary Outcome Measures:
  • Progression-free Survival (PFS) [ Time Frame: From date of randomization to date of disease progression or death, assessed to 17 months ]

    Investigator-assessed PFS is defined as the time from randomization to the date of the first documented progression, as determined by the investigator, or death due to any cause, whichever occurs first. Patients who died without progressing were considered to have progressed on the date of their death.

    Those who did not progress or die were censored on the date of their last evaluable tumor assessment. Patients who did not have any on-study tumor assessments and did not die were censored on their date of randomization. Those who started any subsequent anticancer therapy without a prior reported progression were censored on the date of their last evaluable tumor assessment prior to initiation of subsequent anticancer therapy.

  • Progression-free Survival (PFS) Rate [ Time Frame: Tumor assessments beginning at 9 weeks following randomization and continuing every 6 weeks for the first year, then every 12 weeks thereafter until disease progression or death, assessed to 17 months ]
    The PFS rate at a time point is the estimated percentage of patients who have not progressed and are alive at that time point following randomization and is estimated using the Kaplan-Meier methodology.

  • Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Tumor assessments beginning at 9 weeks following randomization and continuing every 6 weeks for the first year, then every 12 weeks thereafter until disease progression or death, assessed to 17 months ]
    ORR is defined as the percentage of participants with a best overall response of RECIST-defined complete response (CR) or partial response (PR) divided by the number of randomized participants in each treatment arm. RECIST, volume 1.1 for target lesions: CR=disappearance of all target lesions; PR=at least a 30% decrease in the sum of the longest dimension (LD) of target lesions, taking as reference the baseline sum LD; stable disease=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started; PD=at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, and the sum LD must have an absolute increase of ≥5 mm.

  • Overall Survival by Programmed Cell Death Ligand 1 (PD-L1) Expression Level [ Time Frame: From date of randomization to date of disease progression or death, as assessed to 17 months ]
    Overall Survival by PD-L1 expression level, which was defined as the percent of tumor cells demonstrating plasma membrane PD-L1-staining in a minimum of 100 evaluable tumor cells per a Dako PD-L1 IHC assay (referred to as quantifiable PD-L1 expression). Assessment of OS by PD-L1 expression as measured by a validated assay and comparing OS in patients with tumor PD-L1 expression ≥5% versus patients with tumor PD-L1 expression <5%. Tumor tissue samples for PD-L1 testing were collected at screening from metastatic or unresectable sites prior to randomization.

  • Change From Baseline in Health-related Quality of Life (HRQoL) Scores [ Time Frame: At baseline and every 6 weeks for 12 months and at follow-up visits 1 and 2, assessed up to 17 months ]
    HRQoL is evaluated by mean changes from baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) global health status/quality of life composite scale in all randomized patients. The QLQ-30 is a cancer-specific, self-administered questionnaire that contains 30 questions, covering global, functional, and symptom scales. Scores range from 0 to 100. Higher scores on global and functional scales indicate better quality of life (QoL), while higher scores on the symptom scales indicate declining QoL.

Other Outcome Measures:
  • Number of Participants Who Died and With Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, and Drug-related AEs [ Time Frame: Day of first dose to day of final dose + 30 days, assessed up go 17 months ]
    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=having certain, probable, possible, or unknown relationship to study drug.

Enrollment: 583
Study Start Date: January 2013
Estimated Study Completion Date: November 2018
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine
Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks with placebo-matching dacarbazine solution administered IV every 3 weeks, until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion
Biological: BMS-936558 (Nivolumab) Drug: Placebo matching Dacarbazine
Active Comparator: Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab
Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 weeks with placebo-matching nivolumab solution administered IV every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion
Biological: Placebo matching BMS-936558 (Nivolumab) Drug: Dacarbazine


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Men and women ≥18 years of age
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Untreated and histologically confirmed unresectable Stage III or Stage IV melanoma, as per the staging system of the American Joint Committee on Cancer
  • Measurable disease as per Response Evaluation Criteria in Solid Tumors 1.1
  • Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses
  • Known BRAF wild-type, as per regionally acceptable V600 mutational status testing. BRAF mutant patients and those with indeterminate or unknown BRAF status are not permitted to randomize

Exclusion Criteria:

  • Active brain metastases or leptomeningeal metastases
  • Ocular melanoma
  • Any active, known, or suspected autoimmune disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01721772

  Hide Study Locations
Local Institution
Capital Federal, Buenos Aires, Argentina, 1425
Local Institution
Buenos Aires, Argentina, C1426ANZ
Local Institution
Cordoba, Argentina, 5000
Australia, New South Wales
Local Institution
Camperdown, New South Wales, Australia, 2050
Local Institution
Coffs Harbour, New South Wales, Australia, 2450
Local Institution
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Local Institution
Greenslopes, Queensland, Australia, 4120
Local Institution
Southport, Queensland, Australia, 4215
Local Institution
Woolloongabba, Queensland, Australia, 4102
Australia, South Australia
Local Institution
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Local Institution
Malvern, Victoria, Australia, 3144
Local Institution
North Sydney, Australia, 2060
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Canada, British Columbia
Bc Cancer Agency - Vancouver Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Nova Scotia
Qe Ii Health Science Centre
Halfax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Mcgill University, Dept. Oncology
City, Quebec, Canada, H2W 1S6
Local Institution
Santiago, Metropolitana, Chile
Local Institution
Vi?a Del Mar, Valparaiso, Chile
Local Institution
Santiago, Chile, 7630370
Aarhus Universitetshospital
Aarhus, Denmark, 8000
Herlev Hospital
Herlev, Denmark, 2730
Odense University Hospital
Odense C, Denmark, 5000
Helsinki University Hospital
Helsinki, Finland, 00029
Local Institution
Bordeaux, France, 33075
Local Institution
Grenoble, France, 38043
Local Institution
Lille, France, 59037
Local Institution
Montpellier, France, 34295
Local Institution
Paris, France, 75010
Local Institution
Villejuif, France, 94805
Local Institution
Wuerzburg, Bayern, Germany, 97080
Local Institution
Essen, Germany, 45122
Local Institution
Gera, Germany, 07548
Local Institution
Goettingen, Germany, 37075
Local Institution
Heidelberg, Germany, 69120
Local Institution
Kiel, Germany, 24105
Local Institution
Koeln, Germany, 50937
Local Institution
Magdeburg, Germany, 39120
Local Institution
Mainz, Germany, 55131
Local Institution
Nuernberg, Germany, 90419
Local Institution
Recklinghausen, Germany, 45657
Local Institution
Tubingen, Germany, 72076
Local Institution
Athens, Greece, 11527
Local Institution
Neo Faliro, Greece, 18547
Local Institution
Haifa, Israel, 34362
Local Institution
Jerusalem, Israel, 91120
Local Institution
Tel Hashomer, Israel, 52621
Local Institution
Bari, Italy, 70126
Local Institution
Bergamo, Italy, 24127
Local Institution
Genova, Italy, 16132
Local Institution
Meldola (fc), Italy, 47014
Local Institution
Milano, Italy, 20133
Local Institution
Milano, Italy, 20141
Local Institution
Napoli, Italy, 80131
Local Institution
Padova, Italy, 35128
Local Institution
Roma, Italy, 00144
Local Institution
Siena, Italy, 53100
Local Institution
Tlalpan, Distrito Federal, Mexico, 14080
Local Institution
Leon, Guanajato, Guanajuato, Mexico, 37000
Local Institution
Morelia, Michoacan, Mexico
Local Institution
Mexico City, Mexico, CP 003310
Local Institution
Oslo, Norway, 0379
Local Institution
Gdansk, Poland, 80-219
Local Institution
Lodz, Poland, 93-513
Local Institution
Warszawa, Poland, 02-781
Local Institution
San Sebastian, Guipuzcoa, Spain, 20014
Local Institution
Barcelona, Spain, 08036
Local Institution
Madrid, Spain, 28033
Local Institution
Madrid, Spain, 28034
Local Institution
Sevilla, Spain, 41009
Local Institution
Valencia, Spain, 46014
Local Institution
Gothenberg, Sweden, 413 45
Local Institution
Lund, Sweden, 221 85
Local Institution
Umea, Sweden, 901 85
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb Identifier: NCT01721772     History of Changes
Other Study ID Numbers: CA209-066
2012‐003718‐16 ( EudraCT Number )
Study First Received: November 2, 2012
Results First Received: November 20, 2015
Last Updated: October 25, 2016

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017